Treatment of Atrial Fibrillation with Rapid Ventricular Rate

Initial Assessment and Management

The American Heart Association recommends beta blockers as the first-line treatment for atrial fibrillation with rapid ventricular response in hemodynamically stable patients without contraindications 1, 2
For hemodynamically unstable patients, immediate direct-current cardioversion is recommended by the American College of Cardiology 2
In stable patients without heart failure, IV beta blockers or nondihydropyridine calcium channel blockers are recommended for rate control 1, 4
For patients with heart failure with preserved ejection fraction, beta blockers or nondihydropyridine calcium channel blockers are recommended 1, 2
For patients with heart failure with reduced ejection fraction, IV digoxin or amiodarone are recommended as first-line agents 1, 2

Beta blockers are the most effective drug class for rate control, achieving heart rate endpoints in 70% of patients, according to the American Heart Association 4
Nondihydropyridine calcium channel blockers are as effective as beta blockers for acute rate control, as stated by the European Society of Cardiology 4
Digoxin is recommended for patients with heart failure, but is less effective than beta blockers or calcium channel blockers for controlling exercise-induced tachycardia, according to the American College of Cardiology 1, 2
Amiodarone is useful when other measures are unsuccessful or contraindicated, and has both sympatholytic and calcium antagonistic properties, as noted by the European Heart Journal 1, 4, 5

In patients with WPW syndrome and pre-excited AF, prompt direct-current cardioversion is recommended for hemodynamically compromised patients, and IV procainamide or ibutilide for stable patients, according to the American College of Cardiology 2
In COPD patients, nondihydropyridine calcium channel blockers are preferred, as stated by the American Thoracic Society 4, 3
In heart failure patients, beta blockers or nondihydropyridine calcium channel blockers are recommended for HFpEF, and IV digoxin or amiodarone for HFrEF, according to the American Heart Association 1, 2

Combination therapy with digoxin and a beta blocker (or calcium channel blocker for HFpEF patients) is reasonable to control both resting and exercise heart rate, as recommended by the American College of Cardiology 1
AV node ablation may be considered when pharmacological therapy is insufficient or not tolerated, according to the American Heart Association 1, 6

Assessment of heart rate control during exercise and adjustment of treatment is useful in symptomatic patients, as stated by the American College of Cardiology 1
Strict rate control has not been shown to be more beneficial than less strict control, according to the European Society of Cardiology 3

Digoxin has a delayed onset of action and peak effect, making it less suitable for acute rate control, as noted by the American Heart Association 4
In WPW syndrome, using AV nodal blocking agents can lead to preferential conduction through the accessory pathway and precipitate ventricular fibrillation, according to the European Heart Journal 5
For patients who develop heart failure as a result of AF with rapid ventricular response, consider a rhythm-control strategy, as recommended by the American College of Cardiology 6